مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

176
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

162
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

SILYMARIN FOR THE PREVENTION OF CONTRAST‑INDUCED NEPHROPATHY: A PLACEBO‑CONTROLLED CLINICAL TRIAL

Pages

  0-0

Abstract

 Background: SILYMARIN is a flavonoid complex with nephro‑protective properties. We evaluated the efficacy of SILYMARIN in the prevention of contrast‑induced nephropathy (CIN).Methods: This placebo‑controlled clinical trial was conducted on 143 patients with chronic stable angina referring for elective CORONARY ANGIOGRAPHY. Patients with low to moderate risk for CIN were included and were randomized to receive SILYMARIN (280 mg) or placebo 2 h before administration of the contrast material. A nonionic, iso-osmolar contrast material was used. Serum creatinine was measured before and 48 h after injection of the contrast material. CIN was defined as an increase in creatinine of ≥0.5 mg/dL or ≥25% from the baseline.Results: Serum creatinine was increased by 0.02 ± 0.07 mg/dL (P=0.004) with SILYMARIN and by 0.04 ± 0.15 mg/dL (P=0.008) with placebo after contrast material injection (between group difference=0.01 ± 0.02 mg/dL, P=0.881). CIN was occurred less frequently, though statistically nonsignificant, with SILYMARIN compared with placebo (2.9% vs.10.8%, Odds ratio [OR] [95% confidence interval (CI)] =0.246 [0.050–1.203], P=0.099). In the logistic regression analysis controlling for patients characteristics and baseline creatinine level, SILYMARIN was nonsignificantly associated with lower frequency of CIN (OR [95% CI] =0.203 [0.037–1.117], P=0.067).Conclusions: We found a trend toward the efficacy of SILYMARIN in preventing contrast‑induced renal dysfunction. Further trials with larger sample size and in patients with higher risk of CIN are warranted.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    SEDIGHIFARD, ZOHREH, ROGHANI, FARSHAD, BIDRAM, PEYMAN, AALAMI HARANDI, SAMANEH, & MOLAVI, SAFIEH. (2016). SILYMARIN FOR THE PREVENTION OF CONTRAST?INDUCED NEPHROPATHY: A PLACEBO?CONTROLLED CLINICAL TRIAL. INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 7(-), 0-0. SID. https://sid.ir/paper/316465/en

    Vancouver: Copy

    SEDIGHIFARD ZOHREH, ROGHANI FARSHAD, BIDRAM PEYMAN, AALAMI HARANDI SAMANEH, MOLAVI SAFIEH. SILYMARIN FOR THE PREVENTION OF CONTRAST?INDUCED NEPHROPATHY: A PLACEBO?CONTROLLED CLINICAL TRIAL. INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE[Internet]. 2016;7(-):0-0. Available from: https://sid.ir/paper/316465/en

    IEEE: Copy

    ZOHREH SEDIGHIFARD, FARSHAD ROGHANI, PEYMAN BIDRAM, SAMANEH AALAMI HARANDI, and SAFIEH MOLAVI, “SILYMARIN FOR THE PREVENTION OF CONTRAST?INDUCED NEPHROPATHY: A PLACEBO?CONTROLLED CLINICAL TRIAL,” INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, vol. 7, no. -, pp. 0–0, 2016, [Online]. Available: https://sid.ir/paper/316465/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button